Gilead has been at the forefront of helping transform the treatment and prevention of HIV for decades, and it is also focused on helping speed the development and accessibility of new medications for children.
Across the country, LGBTQ+ youth face challenges that are negatively affecting their mental health. Some find themselves not feeling accepted by their family or friends, or being verbally harassed at school.
After finishing medical school in the late 1990s, Bilal Piperdi wanted to follow his mentor into the field of thoracic oncology, the specialized area that focuses on lung cancer.
When LJ Mizzi joined Gilead in 2013, she already had a personal connection to the company. “A Gilead medicine saved the life of a loved one, so I was excited to begin a career here and to contribute in any way I could,” LJ says.
When I came to Gilead in 2019, I did so in part because of the revolutionary way this company thinks about bringing therapies to those who could benefit.
We sat down with Dan Murphy and Dr. Jeffrey Lazarus to discuss the work that needs to be done to meet the United Nations' (U.N.) goal of ending the HIV epidemic by 2030 and to fully meet the needs of people living with HIV around the world.
Gilead’s Corporate Social Responsibility (CSR) Report provides an overview of the work the company is doing around the world to improve the lives of...